Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 9/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699354 | 0.88 | CFTR (0.64) | CFTRRORC | |
| SCHEMBL2371637 | 0.88 | CFTR (0.64) | CFTRRORC | |
| SCHEMBL2372275 | 0.87 | CFTR (0.57) | CFTRMRGPRX4 | |
| SCHEMBL29699295 | 0.87 | CFTR (0.57) | CFTRMRGPRX4 | |
| SCHEMBL27906135 | 0.83 | CFTR (0.47) | CFTRGRM2KDM4CGPBAR1SCN9A | |
| SCHEMBL2372324 | 0.81 | CFTR (0.47) | CFTRGRM2GPBAR1SCN9AMGLL | |
| SCHEMBL14816565 | 0.81 | CFTR (0.52) | CFTRTMPRSS4 | |
| SCHEMBL29699235 | 0.81 | CFTR (0.59) | CFTR | |
| SCHEMBL2372320 | 0.81 | CFTR (0.59) | CFTR | |
| SCHEMBL27906132 | 0.81 | CFTR (0.45) | CFTRGRM2KDM4CGPBAR1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | claimed |
| CN-103930109-B | The substituted heterocyclyl amides of N- | NOVARTIS AG (CH) | 2016-11-30 | — | — | CN | claimed |
| EP-2547656-B1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | claimed |
| US-9056867-B2 | N-substituted heterocyclyl carboxamides | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | claimed |
| EP-2845593-A1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | Novartis AG (CH) | 2015-03-11 | — | — | EP | claimed |
| CN-102892758-B | Pyridine and pyrazine derivatives for the treatment of CF | NOVARTIS AG | 2015-01-07 | — | — | CN | claimed |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | NOVARTIS AG (CH) | 2014-10-30 | — | — | US | claimed |
| CN-103930109-A | N-substituted heterocyclyl carboxamides | NOVARTIS AG | 2014-07-16 | — | — | CN | claimed |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | disclosed |
| CN-113891744-A | Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis | 诺华股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| EP-2755652-B1 | N-SUBSTITUTED HETEROCYCLYL CARBOXAMIDES | NOVARTIS AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
| US-8476269-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2547656-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| CN-102892758-A | Pyridine and pyrazine derivatives for the treatment of CF | NOVARTIS AG | 2013-01-23 | — | — | CN | disclosed |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG | 2012-11-01 | — | — | US | disclosed |
| US-8247436-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2012-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CFTR 1/4885GRM2 3994/4885KDM4C 3418/4885 |
| US-20140323485-A1 | N-Substituted Heterocyclyl Carboxamides | CFTR, AQP1, BDKRB1 | CFTR 1/4885GRM2 4418/4885KDM4C 4243/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | CFTR 1/4885GRM2 3684/4885KDM4C 2935/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | CFTR 1/4885GRM2 4264/4885KDM4C 3629/4885 |
| US-20120277232-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CFTR 1/4885GRM2 3994/4885KDM4C 3418/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CFTR 1/4885GRM2 3994/4885KDM4C 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.